Overview
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder characterized by accelerated aging, primarily due to the accumulation of progerin, a mutant form of lamin A protein, leading to nuclear abnormalities and premature cellular senescence 1.Diagnosis
Clinical features include growth failure, characteristic facial appearance, joint stiffness, and cardiovascular complications.
Genetic testing confirms the LMNA gene mutation responsible for progerin production.
Nuclear morphological abnormalities observed in skin fibroblasts can support diagnosis 1.Management
First-line treatment: Currently, no cure exists; management focuses on supportive care.
Adjunctive treatments: 1α,25-dihydroxyvitamin D3 (1,25D) has shown promise in improving cellular phenotypes by reducing progerin levels and enhancing DNA repair mechanisms 1.Special Populations
Pediatrics: Management strategies are tailored to address growth retardation and developmental delays 1.
Comorbidities: Focus on cardiovascular health due to increased risk of atherosclerosis and stroke 1.Key Recommendations
Consider supplementation with 1α,25-dihydroxyvitamin D3 (1,25D) to potentially mitigate cellular abnormalities and enhance DNA repair in HGPS patients (Evidence: Moderate) 1.
Regular monitoring of cardiovascular health is essential due to the heightened risk of cardiovascular complications in HGPS (Evidence: Expert opinion) 1.
Genetic counseling should be provided to families given the autosomal dominant inheritance pattern of HGPS (Evidence: Expert opinion) 1.References
1 Kreienkamp R, Croke M, Neumann MA, Bedia-Diaz G, Graziano S, Dusso A et al.. Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes. Oncotarget 2016. link